StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

A number of other research firms have also issued reports on CLLS. Oppenheimer lowered their target price on Cellectis from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, June 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $6.00 price objective on shares of Cellectis in a research note on Friday, May 31st.

Cellectis Trading Up 1.5 %

Cellectis stock opened at $2.08 on Friday. Cellectis has a 12-month low of $0.96 and a 12-month high of $3.77. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.63 and a quick ratio of 1.63. The stock has a market capitalization of $115.61 million, a PE ratio of -1.62 and a beta of 3.10. The firm has a 50 day simple moving average of $2.08 and a 200-day simple moving average of $2.51.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. The firm had revenue of $6.50 million for the quarter. As a group, equities research analysts expect that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in Cellectis in the 2nd quarter worth about $29,000. Principal Financial Group Inc. increased its position in shares of Cellectis by 6.2% in the first quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company’s stock worth $1,125,000 after acquiring an additional 24,906 shares in the last quarter. Baillie Gifford & Co. increased its position in shares of Cellectis by 1.3% in the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after acquiring an additional 10,605 shares in the last quarter. Finally, Long Focus Capital Management LLC lifted its position in shares of Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares in the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.